Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,800 Publications201,349 Funding7,267 Clinical research8

Loading search results…

Browse

Scholars8,800 Publications201,349 Funding7,267 Clinical research8

FiltersClear all

Status

Recruiting3
Completed4
Terminated1

Study type

Interventional8

Phase

Phase 28
Not applicable138
Not reported24
Phase 311
Phase 46
Phase 2/33

Investigator

Irina Sobol2
Abhishek Jaywant1
Anthony O. Ahmed1
Faith Gunning1
Grant Ellsworth1

Show all 7Show fewer

Department

Medicine4
Psychiatry3
Rehabilitation Medicine1

Condition

Cognitive Dysfunction2
COVID-191
Colitis, Ulcerative1
Depression1
Familial Primary Pulmonary Hypertension1

Intervention type

Device8
Drug259
Biological43
Other39
Procedure31
Radiation19

Sponsor type

Industry4
WCM (investigator-initiated)3
Cooperative group1

Start date

Has results posted4

Phase 2×Device×Clear all

Showing 1–8 of 8 studiesSort:

RecruitingInterventional · Phase 2NCT05507138 ↗
Efficacy and Target Engagement of a Digital Intervention to Improve Depression and Executive Dysfunction After Stroke
Abhishek Jaywant

FiltersClear all

Status

Recruiting3
Completed4
Terminated1

Study type

Interventional8

Phase

Phase 28
Not applicable138
Not reported24
Phase 311
Phase 46
Phase 2/33

Investigator

Irina Sobol2
Abhishek Jaywant1
Anthony O. Ahmed1
Faith Gunning1
Grant Ellsworth1

Show all 7Show fewer

Department

Medicine4
Psychiatry3
Rehabilitation Medicine1

Condition

Cognitive Dysfunction2
COVID-191
Colitis, Ulcerative1
Depression1
Familial Primary Pulmonary Hypertension1

Intervention type

Device8
Drug259
Biological43
Other39
Procedure31
Radiation19

Sponsor type

Industry4
WCM (investigator-initiated)3
Cooperative group1

Start date

Has results posted4

Phase 2×Device×Clear all

Showing 1–8 of 8 studiesSort:

RecruitingInterventional · Phase 2NCT05507138 ↗
Efficacy and Target Engagement of a Digital Intervention to Improve Depression and Executive Dysfunction After Stroke
Abhishek Jaywant

Joan Stilling1
Randy Longman1

Show all 12

Show fewer

Fatigue1
HIV Seropositivity1
Pulmonary Arterial Hypertension1
Schizophrenia1
Severe combined immunodeficiency with sensitivity to ionizing radiation1
Squamous Intraepithelial Lesions1
Stroke1

Dietary supplement

Intervention: Device: AKL-T01 · Behavioral: Metacognitive Strategy Training
Dates: Mar 2023 – Jun 2027 (est.)
Sponsor: Weill Medical College of Cornell University

Executive DysfunctionDepressionStroke

RecruitingInterventional · Phase 2NCT05816603 ↗

Home-based Post-stroke Fatigue Treatment Using Transcranial Direct Current Stimulation (tDCS)

Joan StillingPI

Intervention: Device: Real Soterix Mini-CT tDCS stimulator · Device: Sham Soterix Mini-CT tDCS stimulator
Dates: May 2023 – Dec 2027 (est.)
Sponsor: Weill Medical College of Cornell University

FatigueStroke Rehabilitaion

RecruitingInterventional · Phase 2NCT06502964 ↗

Double-Blind, Placebo-Controlled Study of ALTO-101 in Patients With Schizophrenia and Cognitive Impairment

Anthony O. AhmedPI

Intervention: Drug: ALTO-101 · Device: ALTO-101 Transdermal Delivery System · Drug: Placebo · Device: Placebo Transdermal Delivery System
Dates: Jun 2024 – Feb 2026 (est.)
Sponsor: Alto Neuroscience

SchizophreniaCognitive Impairment

CompletedInterventional · Phase 2NCT03603808 ↗

A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals

Grant EllsworthPI

Intervention: Device: Electroporation · Biological: HPV DNA Plasmids Therapeutic Vaccine VGX-3100 · Other: Laboratory Biomarker Analysis
Dates: Sep 2018 – Dec 2024· Results posted
Sponsor: AIDS Malignancy Consortium

Anal Intraepithelial NeoplasiaHigh Grade Squamous Intraepithelial NeoplasiaHIV Positivity+2 more

CompletedInterventional · Phase 2NCT04456998 ↗

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

Irina SobolPI

Intervention: Drug: GB002 (seralutinib) · Drug: Placebo · Device: Generic Dry Powder Inhaler
Dates: Nov 2020 – Oct 2022· Results posted
Sponsor: Gossamer Bio

Pulmonary Artery Hypertension

TerminatedInterventional · Phase 2NCT04816604 ↗

An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

Irina SobolPI

Intervention: Drug: GB002 (seralutinib) · Device: Generic Dry Powder Inhaler
Dates: Apr 2021 – Sep 2026
Sponsor: Gossamer Bio

Pulmonary Arterial Hypertension

CompletedInterventional · Phase 2NCT04843930 ↗

Improving Cognitive Health in COVID-19 Survivors Through Digital Therapeutics

Faith GunningPI

Intervention: Device: AKL-T01
Dates: Jul 2021 – Feb 2023· Results posted
Sponsor: Weill Medical College of Cornell University

Cognitive DysfunctionCovid19

CompletedInterventional · Phase 2NCT04996797 ↗

A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy With PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis

Randy LongmanPI

Intervention: Drug: Tulisokibart · Device: Companion Diagnostic (CDx) Testing · Other: Placebo
Dates: Jul 2021 – Jun 2023· Results posted
Sponsor: Prometheus Biosciences, Inc

Ulcerative Colitis